Page 1

September 23 , 2021 IceCure IceCure Medical Reports Financial Results for the First Half of 2021 and Recent Operating Highlights CAESAREA , Israel , Sept. 23 , 2021 / PRNewswire / -- IceCure Medical Ltd. ( NASDAQ : ICCM ) ( TASE : ICCM ) ( " IceCure " or the " Company " ) , developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing , today reported its financial results as of and for the six - month period ended June 30 , 2021 . First Half 2021 and Recent Operating Highlights • The FDA granted Breakthrough Device Designation for the ProSense® system for treatment of various indications , including the use in treatment of patients with T1 invasive breast cancer and / or patients not suitable for surgical alternatives for the treatment of breast cancer . • Presented positive interim results from the ICE3 clinical trial for cryoablation of small low - risk breast cancer tumors using the ProSense System at the 22nd Annual Meeting of the American Society of Breast Surgeons ( ASBRS ) held on April 30 , 2021 . • Continued process with the FDA on a regulatory path forward to make ProSense System available to the breast cancer patients that can benefit from the Company's minimally - invasive cryoablation solution based on the ICE3 clinical trial results . • Peer reviewed article titled " Cryoablation Without Excision for Low - Risk , Early - Stage Breast Cancer : 3 - Year Interim Analysis of Ipsilateral Breast Tumor Recurrence in the ICE3 Trial " was published in the Annals of Surgical Oncology . The lead author of the article was Dr. Richard Fine , MD , FACS , an ICE3 investigator who serves as Program Director of the Breast Surgical Oncology Fellowship and as Director of Research and Education at the West Comprehensive Breast Center in Germantown , TN . • Expanded the Company's global distribution network , including : o Mutlu Medikim Tibbi Malzeme TIC . A.S. ( " Mutlu Medikim A.Ş. " ) to exclusively sell the ProSense System in Turkey . o Novomed Ltd , to distribute the ProSense System in certain parts of India . This represents the Company's second distributor in India . 。 KTRFIOS IMPORTACAO E EXPORTACAO LTDA to exclusively sell the ProSense System in Brazil . o Asian distribution partnership with Terumo Corporation ( Tokyo : 4543 , TRUMY : OTC US ) expanded to include Thailand , in addition to Japan and Singapore . • The R & D team has advanced the development of a next generation systems of single probe system and multi probe system , as compared to the current ProSense System that features one probe . These additional probes will allow the new system to treat bigger tumors or more than one tumor in a patient at the same time . • The Company's ordinary shares commenced trading on the Nasdaq Capital Market on